Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

PURPOSE: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Cuneo, Kyle C., Morgan, Meredith A., Sahai, Vaibhav, Schipper, Matthew J., Parsels, Leslie A., Parsels, Joshua D., Devasia, Theresa, Al-Hawaray, Mahmoud, Cho, Clifford S., Nathan, Hari, Maybaum, Jonathan, Zalupski, Mark M., Lawrence, Theodore S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006846/
https://ncbi.nlm.nih.gov/pubmed/31398082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00730
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars